Comparing Ondansetron Lozenge and Intravenous to Prevent Shivering in Women Undergoing Cesarean Section

What this Trial Is About

Researchers are evaluating the effects of ondansetron lozenge versus intravenous ondansetron for preventing shivering in women undergoing cesarean section with spinal anesthesia. Shivering during and after surgery can increase oxygen use and cause complications like low oxygen levels, lactic acidosis, and interference with heart monitoring. Ondansetron, a selective receptor antagonist, is studied here for its ability to reduce shivering and also lessen nausea and vomiting during and after surgery. Participants are assigned to one of three groups one group receives a 4 mg ondansetron lozenge two hours before surgery, another group receives 8 mg of ondansetron intravenously just before surgery, and a control group does not receive ondansetron. The study follows a randomized, parallel design to compare these methods for preventing shivering. During the study, participants will be monitored for shivering, nausea, vomiting, patient satisfaction, and any adverse effects up to 24 hours after surgery. The primary outcome measured is the incidence of shivering within 24 hours postoperatively. Secondary outcomes include nausea and vomiting rates, satisfaction levels, and any side effects. The total participation lasts through the surgery and 24 hours afterward to assess these outcomes.

Ondansetron Lozenge Versus Intravenous for Prevention of Shivering in Cesarean Section